<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226483</url>
  </required_header>
  <id_info>
    <org_study_id>2016-638N-MA</org_study_id>
    <nct_id>NCT03226483</nct_id>
  </id_info>
  <brief_title>Intraoperative Radiotherapy After the Resection of Brain Metastases</brief_title>
  <acronym>INTRAMET</acronym>
  <official_title>Intraoperative Radiotherapy After the Resection of Brain Metastases - a Phase II Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRAMET examines prospectively the effectiveness of an intraoperative radiotherapy immediate
      after the surgical resection of brain metastases. Patients won't receive further radiation
      therapy of the intraoperatively treated lesion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain metastases occur in up to 40% of all patients diagnosed with systemic cancer. Without
      adjuvant radiotherapy after resection of space occupying lesions local recurrence rates are
      high. That is why guidelines recommend a cavity boosting with x-rays. External beam
      radiotherapy can lower the risk of local recurrence but means longer hospitalization,
      prolongs the time to systemic salvage therapies and bears risks of radionecrosis and
      leucoencephalopathy with neurological and cognitive decline. A solution for this problem
      could be onetime intraoperative radiotherapy (IORT) with soft x-rays to sterilize the
      resection cavity, which may provide both: freedom from local recurrence fast track salvage
      therapy initiation.

      INTRAMET is a single institution, open-label, prospective, phase 2 feasibility study for
      intraoperative radiotherapy immediately following resection of brain metastases. 50 adult
      patients with resectable not dural brain metastases should be treated in surgery after tumor
      resection with IORT with 20-30Gy prescribed to the margin of the resection cavity. The
      highest dose tolerable to surrounding risk structures (N. opticus, brainstem) should be used.

      With this method, the investigators hope to show similar local control rates to postoperative
      external beam radiotherapy in line with guideline recommendations with less patient
      hospitalization and faster start of rescue therapies which could lead to a favorable overall
      outcome and less cognitive side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median local progression-free-survival</measure>
    <time_frame>2 years</time_frame>
    <description>Rate of recurrence of the treated lesion in the brain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall-survival</measure>
    <time_frame>5 years</time_frame>
    <description>Survival differentiated between death due to systemic cancer progress and death due to cerebral progress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to further therapy</measure>
    <time_frame>6 month</time_frame>
    <description>Time to further cancer therapy (e.g. salvage chemotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients cognitive performance</measure>
    <time_frame>5 years</time_frame>
    <description>Neuropsychological battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Patient questionary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global progression-free-survival</measure>
    <time_frame>2 years</time_frame>
    <description>Systemic cancer progression-free-survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional progression-free-survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival concerning other brain metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative radiotherapy caused dose-limiting toxicities</measure>
    <time_frame>6 month after intervention</time_frame>
    <description>Occurrence of wound healing disorders or infection requiring surgical revision, cerebral bleeding or ischemia, radionecrosis requiring surgical intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Intraoperative radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.
To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative Radiotherapy</intervention_name>
    <description>Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.</description>
    <arm_group_label>Intraoperative radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky Performance index ≥ 50%

          -  MRI T1 Gadolinium enhancing non-dural resectable lesion

          -  Informed consent

          -  Adequate birth control

          -  Frozen section confirms metastasis

          -  Adequate distance to optic nerve and brainstem

        Exclusion Criteria:

          -  Dural lesions or meningeal carcinomatosis

          -  Frozen section reveals glioma, lymphoma,small cell lung cancer or germinoma

          -  Psychiatric or social condition interfering compliance

          -  Contraindication against anesthesia, surgery, MRI and/or Gadolinium

          -  Pregnant or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefanie Brehmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Brehmer, MD</last_name>
    <phone>+49 621 383 2750</phone>
    <email>stefanie.brehmer@umm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank A Giordano, MD</last_name>
    <email>frank.giordano@umm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Brehmer, MD</last_name>
      <phone>+49 621 383 2750</phone>
      <email>stefanie.brehmer@umm.de</email>
    </contact>
    <contact_backup>
      <last_name>Frank A Giordano, MD</last_name>
      <email>frank.giordano@umm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefanie Brehmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Giordano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Stefanie Brehmer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Brain Metastases</keyword>
  <keyword>Intraoperative Radiotherapy</keyword>
  <keyword>Neurosurgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

